Hikma Pharmaceuticals/HIK

0.79%
-
1D1W1MYTD1YMAX

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC is a pharmaceutical company. The principal activities of the Company are the development, manufacture and marketing of a range of generic, branded and in-licensed pharmaceutical products. The Company operates through three segments: Injectables, Branded and Generics. The Injectables segment supplies hospitals across its markets with generic injectable products, supported by its manufacturing facilities in the United States, Europe and Middle East/North Africa (MENA). The Branded segment supplies branded generics and in-licensed patented products from its local manufacturing facilities to retail and hospital customers across the MENA region. The Generics segment supplies oral and other non-injectable generic and specialty products to the United States retail market, leveraging its manufacturing facility in Columbus, Ohio. Its subsidiaries include Al Jazeera Pharmaceutical Industry S.A.R.L, Hikma Pharma Algeria S.A.R.L. and others.

Ticker

HIK

Sector

Healthcare

Trading on

LSE

Industry

Biotechnology & Drugs

CEO

Said Darwazah

Employees

8,967

Headquarters

London, United Kingdom

HIK Metrics

BasicAdvanced
£4.89B
Market cap
25.78
P/E ratio
£0.85
EPS
0.43
Beta
£0.72
Dividend rate
3.22%
Dividend yield
£4.89B
0.43481
£27.66
£21.30
652.79K
£0.72
1.568
0.903
46.861
54.186
83.68%
53.304
7.68%
4.2%
8.77%
5.72%
25.779
1.701
2.217
4.454
18.316
1.93%
3.28%
3.22%
17.7%
4.31%
7.09%
-22.15%
-2.46%

What the Analysts think about HIK

Analyst Ratings

Majority rating from 12 analysts.
Buy

Price Targets

Average projection from 10 analysts.
27.68% upside
High £27.85
Low £18.90
£17.88
Current price
£22.83
Average price target

HIK Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
4.07% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$1.45B
1.47%
Net income
$59M
-54.96%
Profit margin
4.07%
-55.66%

HIK Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 11.45%
QuarterlyAnnual
Q4 21
Q2 22
Q4 22
Q2 23
Q4 23
Actual
$0.97
$0.92
$0.88
$1.29
$0.93
Expected
$0.98
$0.95
$0.82
$1.03
$0.83
Surprise
-0.62%
-3.16%
7.32%
24.76%
11.45%
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by ICE Data Services and LSEG. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Hikma Pharmaceuticals stock?

Hikma Pharmaceuticals (HIK) has a market cap of £4.89B as of April 19, 2024.

What is the P/E ratio for Hikma Pharmaceuticals stock?

The price to earnings (P/E) ratio for Hikma Pharmaceuticals (HIK) stock is 25.78 as of April 19, 2024.

Does Hikma Pharmaceuticals stock pay dividends?

Yes, the Hikma Pharmaceuticals (HIK) stock pays dividends to shareholders. As of April 19, 2024, the dividend rate is £0.72258 and the yield is 3.22%. Hikma Pharmaceuticals has a payout ratio of 83.68% on a trailing twelve-month basis.

When is the next Hikma Pharmaceuticals dividend payment date?

The next Hikma Pharmaceuticals (HIK) dividend payment is scheduled for May 03, 2024.

What is the beta indicator for Hikma Pharmaceuticals?

Hikma Pharmaceuticals (HIK) has a beta rating of 0.43. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Hikma Pharmaceuticals stock price target?

The target price for Hikma Pharmaceuticals (HIK) stock is £22.9, which is 28% above the current price of £17.89. This is an average based on projections from 10 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Hikma Pharmaceuticals stock

Buy or sell Hikma Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing